OncoMatch/Clinical Trials/NCT04701645
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Is NCT04701645 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Microdevice for ovarian cancer.
Treatment: Microdevice — This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in ovarian, fallopian tube, and primary peritoneal cancer. The name of the study intervention involved in this study is: -implantable microdevice
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Disease stage
Required: Stage III, IV
Demographics
Lab requirements
Blood counts
absolute neutrophil count ≥ 1,500/mcl; platelets ≥ 75,000/mcl; pt (inr) < 1.5; ptt < 1.5x control
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04701645 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage III or IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages